BACKGROUND AND OBJECTIVE: Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCOGC) is a rare variant of malignant pancreatic tumor. There is still no standardized treatment for this uncommon subtype, as surgical resection with lymphadenectomy is the only potentially curative treatment so far. In this paper, we describe the current knowledge of this very rare specific subtype of pancreatic cancer (PC) as a narrative review. METHODS: For this review, we did not specify the time range of studies referred to due to limited data availability. Our inclusion criteria comprised previous studies, which specifically focused on the rare UCOGC subtype of PC as a confirmed histopathology, either pure or present together with other subtypes. We disregarded the studies involving any other PC subtype but not UCOGC, including undifferentiated and anaplastic carcinomas without osteoclast-like giant cell components. KEY CONTENT AND FINDINGS: The limited available data precludes a definitive assessment of the efficacy of both neoadjuvant and adjuvant chemotherapy in the treatment of UCOGC. Monoclonal antibody pembrolizumab has been proven to be effective in metastatic cases. Multiple cases demonstrate a better overall survival rate for patients with UCOGC only versus those having UCOGC as a component with a pancreatic ductal adenocarcinoma (PDAC) histopathological subtype. The same conclusion can be also drawn comparing the survival rate of patients having pure UCOGC versus UCOGC with associated PDAC. Programmed cell death ligand-1 expression has been shown to be an important determinant, which shortens the survival period of patients diagnosed with UCOGC. CONCLUSIONS: The rarity of UCOGC limits data for clinical courses and treatment plans. We need more data to better understand the relationship between pathogenic mutations, histological subtypes, and prognosis in PC, including UCOGC. Understanding UCOGC's molecular, clinical, radiological, and pathological characteristics can lead to earlier, more accurate diagnoses and better management.

3rd Faculty of Medicine Charles University Prague Czech Republic

Department of General Surgery University Hospital Královské Vinohrady Prague Czech Republic

Toxicogenomics Unit National Institute of Public Health Prague Czech Republic

Zobrazit více v PubMed

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. 10.3322/caac.21834 PubMed DOI

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12-49. 10.3322/caac.21820 PubMed DOI

Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21. 10.1158/0008-5472.CAN-14-0155 PubMed DOI

Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. 4th ed. World Health Organization; 2010.

Moini J, Badolato C, Raheleh Ahangari. Pancreatic Tumors. Elsevier eBooks. 2020 Jan 1;335–58.

Luchini C, Pea A, Lionheart G, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. J Pathol 2017;243:148-54. 10.1002/path.4941 PubMed DOI PMC

Luchini C, Grillo F, Fassan M, et al. Malignant epithelial/exocrine tumors of the pancreas. Pathologica 2020;112:210-26. 10.32074/1591-951X-167 PubMed DOI PMC

Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182-8. 10.1111/his.13975 PubMed DOI PMC

Maksymov V, Khalifa MA, Bussey A, et al. Undifferentiated (anaplastic) carcinoma of the pancreas with osteoclast-like giant cells showing various degree of pancreas duct involvement. A case report and literature review. JOP 2011;12:170-6. PubMed

Gonzalez RS. WHO classification [Internet]. www.pathologyoutlines.com. Available online: https://www.pathologyoutlines.com/topic/pancreaswho.html

Temesgen WM, Wachtel M, Dissanaike S. Osteoclastic giant cell tumor of the pancreas. Int J Surg Case Rep 2014;5:175-9. 10.1016/j.ijscr.2014.01.002 PubMed DOI PMC

Guo YL, Ruan LT, Wang QP, et al. Undifferentiated carcinoma with osteoclast-like giant cells of pancreas: A case report with review of the computed tomography findings. Medicine (Baltimore) 2018;97:e13516. 10.1097/MD.0000000000013516 PubMed DOI PMC

Hrudka J, Kalinová M, Ciprová V, et al. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases. Int J Mol Sci 2024;25:3285. 10.3390/ijms25063285 PubMed DOI PMC

Luchini C, Cros J, Pea A, et al. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Hum Pathol 2018;81:157-65. 10.1016/j.humpath.2018.07.006 PubMed DOI

Imai Y, Morishita S, Ikeda Y, et al. Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases. Pancreas 1999;18:308-15. 10.1097/00006676-199904000-00013 PubMed DOI

Westra WH, Sturm P, Drillenburg P, et al. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 1998;22:1247-54. 10.1097/00000478-199810000-00010 PubMed DOI

Koorstra JB, Maitra A, Morsink FH, et al. Undifferentiated carcinoma with osteoclastic giant cells (UCOCGC) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM). Am J Surg Pathol 2008;32:1905-9. 10.1097/PAS.0b013e31818371cd PubMed DOI PMC

Lewandrowski KB, Weston L, Dickersin GR, et al. Giant cell tumor of the pancreas of mixed osteoclastic and pleomorphic cell type: evidence for a histogenetic relationship and mesenchymal differentiation. Hum Pathol 1990;21:1184-7. 10.1016/0046-8177(90)90157-Z PubMed DOI

Pop RM, Diaconu CI, Rimbaş M, et al. EUS-guided fine needle biopsy is able to provide diagnosis in rare osteoclast-like giant cells undifferentiated carcinoma of the pancreas: report of two cases. Rom J Intern Med 2023;61:116-24. 10.2478/rjim-2023-0008 PubMed DOI

Sedivy R, Kalipciyan M, Mazal PR, et al. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detect Prev 2005;29:8-14. 10.1016/j.cdp.2004.10.006 PubMed DOI

Hirano H, Morita K, Tachibana S, et al. Undifferentiated carcinoma with osteoclast-like giant cells arising in a mucinous cystic neoplasm of the pancreas. Pathol Int 2008;58:383-9. 10.1111/j.1440-1827.2008.02240.x PubMed DOI

Alwaheeb S, Chetty R. Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells. J Clin Pathol 2005;58:987-90. 10.1136/jcp.2004.025221 PubMed DOI PMC

Rusu A, Giuşcă SE, Apostol DGC, et al. Cephalic undifferentiated carcinoma with osteoclast-like giant cells arising from the main pancreatic duct: case report and literature review. Arch Clin Cases 2021;6:6-21. 10.22551/2019.22.0601.10148 PubMed DOI PMC

Manduch M, Dexter DF, Jalink DW, et al. Undifferentiated pancreatic carcinoma with osteoclast-like giant cells: report of a case with osteochondroid differentiation. Pathol Res Pract 2009;205:353-9. 10.1016/j.prp.2008.11.006 PubMed DOI

Molberg KH, Heffess C, Delgado R, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer 1998;82:1279-87. 10.1002/(SICI)1097-0142(19980401)82:7<1279::AID-CNCR10>3.0.CO;2-3 PubMed DOI

Sakhi R, Hamza A, Khurram MS, et al. Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells reported in an asymptomatic patient: a rare case and literature review. Autops Case Rep 2017;7:51-7. 10.4322/acr.2017.042 PubMed DOI PMC

Muraki T, Reid MD, Basturk O, et al. Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated. Am J Surg Pathol 2016;40:1203-16. 10.1097/PAS.0000000000000689 PubMed DOI PMC

Dhall D, Klimstra DS. The cellular composition of osteoclastlike giant cell-containing tumors of the pancreatobiliary tree. Am J Surg Pathol 2008;32:335-7; author response 337. PubMed

Chen CH, Li HN. Undifferentiated Carcinoma with Osteoclast-Like Giant Cells of the Common Bile Duct: A Case Report of a Rare Entity at an Unusual Location. Diagnostics (Basel) 2022;12:1517. 10.3390/diagnostics12071517 PubMed DOI PMC

Deckard-Janatpour K, Kragel S, Teplitz RL, et al. Tumors of the pancreas with osteoclast-like and pleomorphic giant cells: an immunohistochemical and ploidy study. Arch Pathol Lab Med 1998;122:266-72. PubMed

Joo YE, Heo T, Park CH, et al. A case of osteoclast-like giant cell tumor of the pancreas with ductal adenocarcinoma: histopathological, immunohistochemical, ultrastructural and molecular biological studies. J Korean Med Sci 2005;20:516-20. 10.3346/jkms.2005.20.3.516 PubMed DOI PMC

Nai GA, Amico E, Gimenez VR, et al. Osteoclast-like giant cell tumor of the pancreas associated with mucus-secreting adenocarcinoma. Case report and discussion of the histogenesis. Pancreatology 2005;5:279-84. 10.1159/000085283 PubMed DOI

Sakai Y, Kupelioglu AA, Yanagisawa A, et al. Origin of giant cells in osteoclast-like giant cell tumors of the pancreas. Hum Pathol 2000;31:1223-9. 10.1053/hupa.2000.18491 PubMed DOI

Mills K, Birt L, Emery JD, et al. Understanding symptom appraisal and help-seeking in people with symptoms suggestive of pancreatic cancer: a qualitative study. BMJ Open 2017;7:e015682. 10.1136/bmjopen-2016-015682 PubMed DOI PMC

Kane LE, Mellotte GS, Mylod E, et al. Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis. Cancer Res Commun 2022;2:1229-43. 10.1158/2767-9764.CRC-22-0190 PubMed DOI PMC

Rogers HK, Shah SL. Role of Endoscopic Ultrasound in Pancreatic Cancer Diagnosis and Management. Diagnostics (Basel) 2024;14:1156. 10.3390/diagnostics14111156 PubMed DOI PMC

Pancreatic Cancer Treatment (Adult) (PDQ®)–Health Professional Version [Internet]. National Cancer Institute. Cancer.gov; 2020. Available online: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq

Bassi C, Salvia R, Butturini G, et al. Value of regional lymphadenectomy in pancreatic cancer. HPB (Oxford) 2005;7:87-92. 10.1080/13651820510028855 PubMed DOI PMC

Demetter P, Maréchal R, Puleo F, et al. Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far? Front Oncol 2021;11:630086. 10.3389/fonc.2021.630086 PubMed DOI PMC

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. 10.1056/NEJMoa1011923 PubMed DOI

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-24. 10.1016/S0140-6736(16)32409-6 PubMed DOI

Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v56-68. 10.1093/annonc/mdv295 PubMed DOI

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. 10.1056/NEJMoa1304369 PubMed DOI PMC

Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol 2023;20:318-37. 10.1038/s41571-023-00746-1 PubMed DOI

Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. 10.1093/jnci/djz073 PubMed DOI PMC

Mylonakis A, Driva TS, Lykoudis P, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: An individual participant data meta-analysis. Ann Hepatobiliary Pancreat Surg 2024;28:125-33. 10.14701/ahbps.23-161 PubMed DOI PMC

Igarashi Y, Gocho T, Taniai T, et al. Conversion surgery for undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a case report. Surg Case Rep 2022;8:42. 10.1186/s40792-022-01385-x PubMed DOI PMC

Imaoka H, Ikeda M, Maehara K, et al. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer 2020;20:946. 10.1186/s12885-020-07462-4 PubMed DOI PMC

Obayashi M, Shibasaki Y, Koakutsu T, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report. BMC Gastroenterol 2020;20:220. 10.1186/s12876-020-01362-4 PubMed DOI PMC

Besaw RJ, Terra AR, Malvar GL, et al. Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells. J Natl Compr Canc Netw 2021;19:247-52. 10.6004/jnccn.2021.7001 PubMed DOI

Hrudka J, Lawrie K, Waldauf P, et al. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature. Virchows Arch 2020;477:687-96. 10.1007/s00428-020-02830-8 PubMed DOI

Cai Y, Chen Y, Wu X, et al. Seven-year disease-free survival in a patient with osteoclast-like giant cell-containing pancreatic undifferentiated carcinoma: a case report and literature review. Int J Clin Exp Pathol 2020;13:3200-5. PubMed PMC

Gao HQ, Yang YM, Zhuang Y, et al. Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas. World J Gastroenterol 2015;21:694-8. 10.3748/wjg.v21.i2.694 PubMed DOI PMC

Kobayashi S, Nakano H, Ooike N, et al. Long-term survivor of a resected undifferentiated pancreatic carcinoma with osteoclast-like giant cells who underwent a second curative resection: A case report and review of the literature. Oncol Lett 2014;8:1499-504. 10.3892/ol.2014.2325 PubMed DOI PMC

Strobel O, Hartwig W, Bergmann F, et al. Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. Surgery 2011;149:200-8. 10.1016/j.surg.2010.04.026 PubMed DOI